gene therapy

News

Former Alexion CEO Hallal makes comeback at cell therapy hol...

Massachusetts holding company ElevateBio has launched with $150m in initial funding from a range of investors on a mission to build a portfolio of cell and gene therapy companies.<

News

Second death in gene therapy trial prompts investigation

A second death in a study of Novartis’ spinal muscular atrophy gene therapy Zolgensma (onasemnogene abeparvovec-xioi; AVXS-101) – a potential blockbuster for this rare disease – has prompte

News

Catalent acquires gene therapy specialist Paragon for $1.2bn

Drug delivery technology provider Catalent is to acquire gene therapy company Paragon for $1.2 billion.

News

Roche insists Spark deal is still on, despite lacklustre tak...

Shareholders in Spark Therapeutics haven’t been queueing up to take advantage of Roche’s $114.50-per-share offer, forcing an extension to the tender process.

News

health care icon pattern medical innovation concept background design

UK health innovations get £23m funding

The UK government’s Biomedical Catalyst (BMC) programme has announced £23 million of funding for cutting edge health projects, including new software which enables radiologists to diagnose

Views & Analysis

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

Gene addition – a new chapter in treating rare diseases

The scientific advancements of the past 30 years have transformed our understanding of the potential of gene therapy and how it may be used to tackle rare diseases.

Former Alexion CEO Hallal makes comeback at cell therapy hol...

Second death in gene therapy trial prompts investigation

Catalent acquires gene therapy specialist Paragon for $1.2bn

Roche insists Spark deal is still on, despite lacklustre tak...

UK health innovations get £23m funding

Gene addition – a new chapter in treating rare diseases

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

gene therapy

Editor's Picks